Top

Published in:

01-08-2018 | Review

The role of radiation therapy in the treatment of metastatic cancer

Authors: Baldassarre Stea, Tijana Skrepnik, Charles C. Hsu, Roy Abendroth

Published in: Clinical & Experimental Metastasis | Issue 5-6/2018

Abstract

Radiation therapy continues to play an important role in the management of cancer. In this review, we discuss the use of radiation therapy to target and control micrometastatic disease (adjuvant use of radiation), or using stereotactic radiation therapy to address small volumes of gross disease, such as oligometastases, and finally the use of radiation therapy in the era of immunotherapy. Radiation therapy is commonly used to treat nodal basins suspected of harboring microscopic disease. More recently, computer and technical innovations have allowed radiation oncologists to treat small volumes of gross disease within the brain and also in the body with great success, adding to the cancer armamentarium. This modality of cancer treatment that began shortly after the discovery of X-rays by William Roentgen continues to evolve and finds new clinical applications which minimize toxicity while increasing effectiveness. The newly discovered interactions of high dose/fraction radiation (stereotactic radiosurgery) with immune check point inhibitors in melanoma is the latest example of how synergism can be achieved between two different modalities thus increasing the therapeutic ratio to control metastatic cancer.

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER cancer statistics review, 1975–2014, National Cancer Institute. Bethesda. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. SEER cancer statistics review, 1975–2014. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017

Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R, IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions (2017) The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 12:1109–1121. https://doi.org/10.1016/j.jtho.2017.04.011 CrossRefPubMed

Morgensztern D, Ng SH, Gao F, Govindan R (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:29–33. https://doi.org/10.1097/JTO.0b013e3181c5920c CrossRefPubMed

Fisher B (1999) From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 35:1963–1973CrossRefPubMed

Rabinovitch R, Kavanagh B (2009) Double helix of breast cancer therapy: intertwining the Halsted and Fisher hypotheses. J Clin Oncol 27:2422–2423. https://doi.org/10.1200/JCO.2009.21.8453 CrossRefPubMed

Paget S (1989) The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8:98–101PubMed

Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84. https://doi.org/10.1016/j.lungcan.2014.07.020 CrossRefPubMed

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee S-M, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O’Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C, TRACERx Consortium (2017) Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376:2109–2121. https://doi.org/10.1056/NEJMoa1616288 CrossRefPubMed

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8 CrossRefPubMed

10.

Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382. https://doi.org/10.1038/nrclinonc.2011.44 CrossRefPubMed

11.

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357. https://doi.org/10.1038/nature14347 CrossRefPubMedPubMedCentral

12.

Stephens SJ, Moravan MJ, Salama JK (2018) Managing patients with oligometastatic non-small-cell lung cancer. J Oncol Pract 14:23–31. https://doi.org/10.1200/JOP.2017.026500 CrossRefPubMed

13.

Divisi D, Barone M, Zaccagna G, Gabriele F, Crisci R (2018) Surgical approach in the oligometastatic patient. Ann Transl Med 6:94. https://doi.org/10.21037/atm.2018.01.19 CrossRefPubMedPubMedCentral

14.

Niibe Y, Hayakawa K (2010) Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 40:107–111. https://doi.org/10.1093/jjco/hyp167 CrossRefPubMedPubMedCentral

15.

Griffioen GHMJ, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA (2013) Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 82:95–102. https://doi.org/10.1016/j.lungcan.2013.07.023 CrossRefPubMed

16.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501. https://doi.org/10.1001/jamaoncol.2017.3501 CrossRefPubMed

17.

Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824–3830. https://doi.org/10.1200/JCO.2014.56.7412 CrossRefPubMed

18.

Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0 CrossRefPubMedPubMedCentral

19.

Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, Eaton D, Faivre-Finn C, Fenwick J, Forster M, Hanna GG, Harden S, Mayles P, Moinuddin S, Landau D (2018) Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open 8:e020690. https://doi.org/10.1136/bmjopen-2017-020690 CrossRefPubMedPubMedCentral

20.

De Ruysscher D, Wanders R, van Baardwijk A, Dingemans A-MC, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547–1555. https://doi.org/10.1097/JTO.0b013e318262caf6 CrossRefPubMed

21.

Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, Weichselbaum RR, Kao J, Urbanic JJ, Milano MT, Chmura SJ, Salama JK (2018) Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis. PLoS ONE 13:e0195149. https://doi.org/10.1371/journal.pone.0195149 CrossRefPubMedPubMedCentral

22.

Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385:36–42. https://doi.org/10.1016/S0140-6736(14)61085-0 CrossRefPubMed

23.

Slotman BJ, Faivre-Finn C, van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M, van Dam I, van der Leest A, Reymen B, Stigt J, Haslett K, Tripathi D, Smit EF, Senan S (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer 108:150–153. https://doi.org/10.1016/j.lungcan.2017.03.007 CrossRefPubMed

24.

Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, Higgins KA, Werner-Wasik M, Allen AM, Iyengar P, Videtic GMM, Hales RK, McGarry RC, Urbanic JJ, Pu AT, Johnstone CA, Stieber VW, Paulus R, Bradley JD (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol 12:1561–1570. https://doi.org/10.1016/j.jtho.2017.06.015 CrossRefPubMedPubMedCentral

25.

Torok JA, Gu L, Tandberg DJ, Wang X, Harpole DH, Kelsey CR, Salama JK (2017) Patterns of distant metastases after surgical management of non-small-cell lung cancer. Clin Lung Cancer 18:e57–e70. https://doi.org/10.1016/j.cllc.2016.06.011 CrossRefPubMed

26.

Luketich JD, Burt ME (1996) Does resection of adrenal metastases from non-small cell lung cancer improve survival? Ann Thorac Surg 62:1614–1616CrossRefPubMed

27.

Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D’Angelica MI, Brennan MF, Strong VE (2018) Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease. Ann Surg. https://doi.org/10.1097/SLA.0000000000002749 CrossRef

28.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EEW, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118:2962–2970. https://doi.org/10.1002/cncr.26611 CrossRefPubMed

29.

Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2(7 suppl3):S94–S100. https://doi.org/10.1097/JTO.0b013e318074de34 CrossRefPubMed

30.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–1076. https://doi.org/10.1001/jama.2010.261 CrossRefPubMedPubMedCentral

31.

Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M (2014) Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol 25:1954–1959. https://doi.org/10.1093/annonc/mdu370 CrossRefPubMed

32.

Chmura SJ, Winter KA, Salama JK, Woodward WA, Borges VF, Al-Hallaq HA, Matuszak M, Jaskowiak NT, Milano MT, Bandos H, White JR (2016) NRG BR002: a phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. J Clin Oncol 34:TPS1098CrossRef

33.

Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–484CrossRefPubMed

34.

Arriagada R, Le Chevalier T, Borie F et al (1995) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 87:183–190CrossRefPubMed

35.

Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 16(9):1049–1060. https://doi.org/10.1016/S1470-2045(15)00187-4 CrossRefPubMed

36.

Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 77(3):655–661

37.

Sandru A, Voinea S, Panaitescu E, Blidaru A (2014) Survival rates of patients with metastatic malignant melanoma. J Med Life 7(4):572–576PubMedPubMedCentral

38.

Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving Ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368–375CrossRefPubMedPubMedCentral

39.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL (2016) Effect of radiosurgery vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409. https://doi.org/10.1001/jama.2016.9839 CrossRefPubMedPubMedCentral

40.

Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Investig 120(5):1368–1379. https://doi.org/10.1172/JCI41911 CrossRefPubMedPubMedCentral

41.

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560):337–341. https://doi.org/10.1038/nature14432 CrossRefPubMedPubMedCentral

42.

Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421. https://doi.org/10.1038/nature12477. Erratum in: Nature 502(7470):258CrossRefPubMedPubMedCentral

43.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Version 2.2018-Jan 19, 2018. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf

44.

Tawbi H et al (2017) Efficacy and safety of nivolumab (NIVO) plus Ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. In: ASCO proceedings

45.

Long G et al (2017) A randomized phase II study of nivolumab or nivolumab combined with Ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC). In: ASCO proceedings

46.

Herskind C, Wenz F, Giordano FA (2017) Immunotherapy combined with large fractions of radiotherapy: SRS for BM—implications for IORT after resection. Front Oncol 7:147. https://doi.org/10.3389/fonc.2017.00147 CrossRefPubMedPubMedCentral

47.

Schaue D, Ratikan JA, Iwamoto KS, McBride WH (2012) Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83(4):1306–1310. https://doi.org/10.1016/j.ijrobp.2011.09.049 CrossRefPubMed

48.

Azad A, Yin Lim S, D’Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, Muschel RJ, Fokas E (2017) PD-L1 blockade enhances response of pancreatic ducal adenoCa to RT. EMBO Mol Med 9(2):167–180. https://doi.org/10.15252/emmm.201606674 CrossRefPubMed

49.

Tyman-Saint Victor C, Rech AJ, Maity A, Rengan R et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373–377. https://doi.org/10.1038/nature14292 CrossRef

50.

Demaria S, Bhardwaj N, McBride WH, Formenti SC (2005) Combining RT and IT: a revived partnership. Int J Radiat Oncol Biol Phys 63(3):655–666CrossRefPubMedPubMedCentral

51.

Formenti SC, Demaria S (2012) Radiation therapy to convert the tumor into an in-situ vaccine. Int J Radiat Oncol Biol Phys 84(4):879–880. https://doi.org/10.1016/j.ijrobp.2012.06.020 CrossRefPubMed

52.

Nguyen SM, Castrellon A, Vaidis O, Johnson AE (2017) Stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone in melanoma brain metastases. Cureus 9(7)

53.

Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, Khosa F, Liu Y, Khan MK (2017) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40(5):444–450. https://doi.org/10.1097/COC.0000000000000199 CrossRefPubMed

54.

Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, McDermott DF, Kaplan ID (2015) Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer. https://doi.org/10.1186/s40425-015-0095-8 CrossRefPubMedPubMedCentral

55.

Qian JM, Yu JB, Kluger HM, Chiang VL (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of MBM to SRS. Cancer 122(19):3051–3058. https://doi.org/10.1002/cncr.30138 CrossRefPubMed

56.

Anderson E, Postow MA, Wolchok JD, Young RJ, Ballangrud Å, Chan TA, Yamada Y, Beal K (2017) Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer. https://doi.org/10.1186/s40425-017-0282-x CrossRefPubMedPubMedCentral

57.

Skrepnik T, Sundararajan S, Cui H, Stea B (2017) Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology 6(3):e1283461. https://doi.org/10.1080/2162402X.2017.1283461 CrossRefPubMedPubMedCentral

58.

Fertil B, Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys 11:1699–1707CrossRefPubMed

59.

Szumiel I (2008) Intrinsic radiation sensitivity: cellular signaling is the key. Radiat Res 169:249–258CrossRefPubMed

Title: The role of radiation therapy in the treatment of metastatic cancer
Authors: Baldassarre Stea
Tijana Skrepnik
Charles C. Hsu
Roy Abendroth
Publication date: 01-08-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5-6/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9926-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2018

Update on the indications and results of sentinel node mapping in upper GI cancer

Metastatic gynecologic malignancies: advances in treatment and management

Breast cancer metastasis through the lympho-vascular system

Cancer initiation and progression within the cancer microenvironment

Lymphedema surgery: the current state of the art

Genetics of metastasis: melanoma and other cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer